Syneron Candela Launches "Changing Lives" Program At AAD

Company Donating Funds To Worthy Causes, One Registrant At A Time

17 Mar, 2015, 09:00 ET from Syneron Medical Ltd.

IRVINE, Calif., March 17, 2015 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), a global market leader in the aesthetic medical device marketplace, today announced the introduction of the Changing Lives Program, a corporate wide initiative that leverages the company's life-changing technologies with life-changing causes. Launching at the annual American Academy of Dermatology (AAD) meeting in San Francisco on March 21, Changing Lives empowers all 7,000 AAD registrants to select the recipients of Syneron Candela's charitable donations. 

Life-Changing Technology Dedicated To Life-Changing Causes 
Donating to the charity of your choice is easy. Pick up the company's door drop, select your charity and leave the card at the Syneron Candela Booth, 1014; the company will make a direct donation to these causes. "We are not only proud of the outcomes generated by our devices for those in need, we are pleased when we can give back to the community, sharing solutions that make a difference," comments Amit Meridor, CEO of Syneron Candela.

Changing Lives Charitable Choices Include: 

Project New Start sponsored by PicoWay 
Project New Start, a program of Alameda County, CA, helps at-risk young people make positive life changes, including assisting them in the removal of gang-related tattoos.  Syneron Candela's PicoWay PicoSecod tattoo removal system emits the shortest pulses destroying even the smallest ink particles resulting in faster clearance, and fewer treatments, making it the device of choice for tattoo removal.  Featuring two wavelengths, PicoWay is FDA cleared to treat most ink colors on all skin types.

Dress for Success sponsored by UltraShape® and VelaShape® III 
Dress for Success is a national organization that helps disadvantaged women enter the workforce by providing them with career tools, professional attire and a boost to their self-esteem.

UltraShape uses focused ultrasound technology to destroy fat cells, helping individuals regain confidence by losing up to two full sizes with minimal discomfort, no downtime and no visible signs of treatment.

VelaShape III combines three technologies for safe, effective body contouring. Patients see a dramatic reduction in cellulite and circumference, and new features ensure enhanced performance in fewer sessions.

The Vascular Birthmarks Foundation sponsored by Vbeam® Perfecta 
The Vascular Birthmarks Foundation helps ensure the diagnosis and treatment of children born with hemangiomas and other vascular abnormalities.

The VBeam Perfecta is the world's best-known and most popular laser for the treatment of vascular abnormalities. Vbeam Perfecta is gentle enough to be FDA cleared to treat delicate infant skin.  The VBeam Perfecta is the "gold standard" for laser treatment of vascular lesions for infants, children and adults of all ages.

Camp Discovery sponsored by elos Plus® 
Camp Discovery, a program of the AAD, provides a wealth of outdoor activities for children living with skin diseases—free of charge.

elōs Plus is the complete aesthetic workstation, fully upgradeable and able to provide medical and aesthetic applications ranging from skin rejuvenation, color correction, permanent hair reduction and more.

The Henry Jackson Foundation sponsored by GentleMax Pro® 
The Henry Jackson Foundation is a global organization dedicated to advancing military medical research.

GentleMax Pro has been used to deliver safe, effective, permanent hair reduction on all skin types. It is especially effective when used with amputees as it increases the comfort of wearing a prosthetic limb. With patented DCD™ cooling, GentleMax Pro removes unwanted hair and is also FDA cleared for the treatment of pigmented and vascular lesions.

The Joseph M. Still Burn Center sponsored by CO2RE® 
The Joseph M. Still Burn Center treats more than 2,000 patients who suffer burns annually—one-third of whom are children—with a variety of treatments, including CO2RE.

CO2RE is the fractional CO2 system that enables precise targeting and effective treatment at the surface, middle and deep dermal levels. CO2RE also offers traditional CO2 resurfacing and laser excision of lesions.

Through the Changing Lives Program, Syneron Candela is proud to support these organizations; device work does more than improve looks. Curious? Stop by the company's booth, #1014, during AAD to learn more, and let us make a donation on your behalf.

About Syneron Candela 
Syneron Candela is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint.  The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, tattoo removal, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under three distinct brands, Syneron, Candela and CoolTouch, and has a wide portfolio of trusted, leading products including UltraShape, VelaShape, GentleLase, VBeam Perfecta, PicoWay and elōs Plus.

Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Candela are located in Israel. Syneron Candela also has R&D and manufacturing operations in the U.S.  The company markets, services and supports its products in 86 countries.  It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.

For additional information, please visit http://www.syneron-candela.com.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including product efficacy, market acceptance of new products, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Company's most recent Annual Report on Form 20-F, and in the filings that Syneron Medical makes with the SEC, and other factors beyond the Company's control. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from those expressed or implied by these forward-looking statements.  These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.

Contacts:

Syneron Medical – Public Relations
pr@syneron.com  

Zack Kubow, The Ruth Group zkubow@theruthgroup.com, 646-536-7020
Hugo Goldman, Chief Financial Officer, Syneron Hugo.Goldman@syneron.com  

KELZ PR, 646-450-5359
Melissa Ben-Yoseph, Melissa@kelzpr.com 
Patty Mathews, Pattymathews@kelzpr.com 

Logo - http://photos.prnewswire.com/prnh/20120528/535447

SOURCE Syneron Medical Ltd.